ENDRA Life Sciences (NASDAQ:NDRA) Shares Down 5.1% – Time to Sell?

ENDRA Life Sciences Inc. (NASDAQ:NDRA) shares were down 5.1% during trading on Monday . The stock traded as low as $3.70 and last traded at $3.75. Approximately 11,455 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 21,055 shares. The stock had previously closed at $3.95.

Analysts Set New Price Targets

A number of research firms have weighed in on NDRA. Wall Street Zen upgraded ENDRA Life Sciences to a “sell” rating in a report on Saturday, November 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ENDRA Life Sciences in a research note on Wednesday, January 21st. Finally, Ascendiant Capital Markets decreased their price objective on ENDRA Life Sciences from $38.00 to $30.00 and set a “buy” rating for the company in a report on Monday, December 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, ENDRA Life Sciences presently has an average rating of “Hold” and an average target price of $30.00.

ENDRA Life Sciences Stock Down 5.1%

The firm has a fifty day moving average price of $4.35 and a two-hundred day moving average price of $4.98. The stock has a market capitalization of $2.81 million, a P/E ratio of -0.14 and a beta of 0.01.

Hedge Funds Weigh In On ENDRA Life Sciences

An institutional investor recently bought a new position in ENDRA Life Sciences stock. Altium Capital Management LLC bought a new position in ENDRA Life Sciences Inc. (NASDAQ:NDRA) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 51,900 shares of the company’s stock, valued at approximately $235,000. ENDRA Life Sciences accounts for about 0.9% of Altium Capital Management LLC’s holdings, making the stock its 17th largest holding. Altium Capital Management LLC owned about 6.92% of ENDRA Life Sciences at the end of the most recent quarter. Institutional investors own 1.19% of the company’s stock.

About ENDRA Life Sciences

ENDRA Life Sciences, Inc (NASDAQ: NDRA) is a medical technology company headquartered in Ann Arbor, Michigan, that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS™) imaging. The company’s proprietary TAEUS platform combines conventional ultrasound with thermoacoustic signals to provide non-invasive, real-time temperature monitoring of soft tissue. This technology is designed to improve the safety, efficacy and outcomes of thermal ablation procedures and other heat-based therapies.

ENDRA’s core product line centers on a compact, easy-to-integrate device that augments existing ultrasound systems.